沙库巴曲缬沙坦钠治疗CHD合并CHF的疗效研究

The Efficacy of Sacubitril Valsartan Sodium Tablets in the Treatment of CHD Combined with CHF

目的研究沙库巴曲缬沙坦钠治疗冠心病(CHD)合并慢性心力衰竭(CHF)的疗效。方法选取2022年1月-2023年12月在中国人民解放军联勤保障部队第九八八医院诊治的CHD合并CHF患者114例,区组随机法分为对照组(常规治疗,57例)和研究组(常规+沙库巴曲缬沙坦钠治疗,57例),比较两组疗效、心功能、炎性因子水平、生活质量和不良反应。结果研究组临床总有效率显著高于对照组(χ^(2)=5.911,P<0.05)。治疗12周后,研究组左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)降低,左室射血分数(LVEF)升高,研究组LVESD、LVEDD明显低于对照组(P<0.05),LVEF明显高于对照组(P<0.05)。治疗12周后,两组炎性因子肿瘤坏死因子-α(TNF-α)、高敏C反应蛋白(hs-CRP)、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)显著下降,研究组TNF-α、hs-CRP、IL-1β、IL-6明显低于对照组(P<0.05)。治疗12周后,两组6 min步行距离(6MWT)显著提升(P<0.05),明尼苏达州心力衰竭生活质量问卷(MLHFQ)评分显著降低(P<0.05),研究组6MWT明显高于对照组,MLHFQ明显低于对照组(P<0.05)。结论沙库巴曲缬沙坦钠可有效增强CHD合并CHF患者心功能,通过降低TNF-α、IL-1β、IL-6等炎性因子水平,进一步改善患者的整体健康状况和生活质量。

Objective To investigate the efficacy of sacubitril valsartan sodium tablets in the treatment of coronary heart disease(CHD)complicated with chronic heart failure(CHF).Methods One hundred and fourteen patients with CHD combined with CHF who were treated in our hospital during the period from January 2022 to December 2023 were selected and divided into the control group(conventional treatment,57 cases)and the study group(conventional+sacubitril valsartan sodium tablets treatment,57 cases)by using the district group randomisation method.The efficacy,cardiac function,inflammatory factor levels,quality of life and adverse reactions were compared between the two groups.Result The total clinical effective rate of the study group was significantly higher than that of the control group(χ^(2)=5.911,P<0.05).After 12 weeks of treatment,the left ventricular end systolic diameter(LVESD)and left ventricular end diastolic diameter(LVEDD)in the study group decreased,and the left ventricular ejection fraction(LVEF)increased.The LVESD and LVEDD in the study group were lower than those in the control group(P<0.05),and the LVEF was higher than that in the control group(P<0.05).After 12 weeks of treatment,the inflammatory factors tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs CRP),interleukin-1β(IL-1β),and interleukin-6(IL-6)in both groups significantly decreased,and the levels of TNF-α,hs CRP,IL-1β,and IL-6 in the study group were lower than those in the control group(P<0.05).After 12 weeks of treatment,the 6-minute walking distance(6MWT)of both groups significantly increased(P<0.05),and the Minnesota Heart Failure Quality of Life Questionnaire(MLHFQ)score significantly decreased(P<0.05).The 6MWT of the study group was higher than that of the control group,and the MLHFQ was lower than that of the control group(P<0.05).There was no significant difference in the overall incidence of adverse reactions between the two groups(P>0.05).Conclusion Sacubitril valsartan sodium tablets for patients with CHD combined with CHF can effectively enhance cardiac function and further improve the overall health and quality of life of patients by lowering the levels of inflammatory factors such as TNF-α,IL-1β and IL-6.